Cencora Ventures

What Cencora Ventures does

Cencora Ventures is a $150 million corporate venture fund and the strategic investment vehicle of Cencora, Inc. (NYSE: COR, formerly AmerisourceBergen). Originally established as AB Health Ventures prior to the parent's August 2023 rebrand to Cencora, the fund invests in and provides commercial support to early- and growth-stage healthcare startup companies. The fund's purpose is explicitly strategic — to back entrepreneurial firms advancing healthcare for humans and animals — rather than purely financial returns-driven.

The fund does not develop proprietary products or technology. Its economic engine is equity participation in funding rounds alongside other specialized healthcare and CVC investors, combined with commercial support that leverages Cencora's global distribution network, regulatory expertise, and industry relationships to accelerate portfolio company growth. Active portfolio companies span oncology (RISA Labs, Atropos Health), community-based advanced therapy delivery (NexCure), specialty care (House RX, Lumata Health), patient access and adherence (Sempre Health), and clinical trial diversity (Acclinate). Legacy positions include Annexus Health, MRN, Prescribewellness, Trakcel, and Vetsource, the last of which signals animal health exposure beyond human healthcare.

The fund is operated under a co-management model with Cerity Partners Ventures, blending Cencora's healthcare domain team (Jason Dinger, Jenni Zilka) with dedicated CVC managers (Kindra Tatarsky, Colin Tasi, Abigail Risse). Its claimed geographic scope is global, spanning North and South America, Europe, and Asia Pacific, though specific portfolio company geographies are US-centric in the disclosed data. Recent deployment activity — co-leading RISA Labs' $11.1M Series A in January 2026 and participating in NexCure's $19M Series A in March 2026 — demonstrates an active investment cadence into healthcare AI and advanced therapy delivery models.

Name

Cencora Ventures

Legal name

Cencora Ventures (operating name of Cencora, Inc.)

Website

https://cencoraventures.cencora.com

Company type

Private

Founded year

2023

Operating status

Operating

Short description

Cencora Ventures is a $150 million corporate venture fund backed by Cencora, Inc. (NYSE: COR) that invests in and provides commercial support to early- and growth-stage healthcare startups across oncology, cell and gene therapy, AI-enabled healthcare delivery, and animal health.

Ownership category

akta.pro rank

Product category

Corporate Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

akta.pro secondary industry

Corporate Venture Studios & Incubators (Build/launch ventures) (FSANAHAC)

Keywords

• Corporate venture capital
• Healthcare startup investing
• Venture fund management
• Healthtech equity investment
• Commercial portfolio support

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Investment Returns: Cencora Ventures generates returns through equity investments in early-stage and emerging healthcare companies. The fund participates in funding rounds and provides commercial support to portfolio companies, benefiting from their growth and eventual exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Cencora Ventures is a $150 million corporate venture fund that invests equity capital in early-stage and growth-stage healthcare startup companies and provides those portfolio companies with commercial support drawn from Cencora's healthcare industry expertise, distribution networks, and global scale. Originally established as AB Health Ventures by AmerisourceBergen and renamed in August 2023 to align with the parent's rebrand to Cencora, the fund is co-managed with Cerity Partners Ventures and targets entrepreneurial firms positioned to advance human and animal health outcomes.

Product overview

Cencora Ventures is a $150 million corporate venture fund that invests in and provides commercial support to emerging healthcare startup companies. The fund, formerly known as AB Health Ventures, was originally started by AmerisourceBergen prior to rebranding as Cencora in August 2023. The fund does not offer its own branded products; rather, it supports portfolio companies including RISA Labs, Acclinate, Atropos Health, House RX, Lumata Health, Sempre Health, Annexus Health, MRN, Prescribe Wellness, TrakCel, and Vetsource. The portfolio spans AI operating systems for oncology, patient relationship management, decentralized clinical trials, cell and gene therapy orchestration, and veterinary services.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Fund has invested in multiple healthcare startups including NexCure ($19M Series A), RISA Labs ($11.1M Series A), and other portfolio companies across oncology, cell and gene therapy, and healthcare administration.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Cerity Partners VenturescoreStrategic or Co-development PartnerCerity Partners Ventures manages Cencora Ventures alongside Cencora. The partnership brings significant healthcare industry and corporate venture capital experience, with the combined team maximizing value for startups to keep healthcare moving forward.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Optum Ventures: Corporate venture arm of UnitedHealth Group/Optum focused on healthcare technology and services. Direct peer to Cencora Ventures as a healthcare CVC, frequently co-invests (e.g., co-led RISA Labs' Series A with Cencora Ventures) and shares the same strategic-vs-financial return tension.
• Echo Health Ventures: Strategic CVC partnership formed by Cambia Health Solutions and Blue Cross NC. Direct peer to Cencora Ventures as a healthcare-focused corporate venture fund combining strategic capital with operating-company value-add, similar size and stage focus.
• RA Capital Management: Healthcare-focused crossover and venture fund. Direct peer given healthcare focus and co-investment relationship (led NexCure's $19M Series A with Cencora Ventures participating). Comparable deal flow and stage preferences.
• McKesson Ventures: Corporate venture arm of McKesson, the other major US pharmaceutical distributor alongside Cencora. The closest direct peer given near-identical industry positioning, fund structure, and healthcare distribution strategic value-add.
• Cardinal Health Innovation Fund: Innovation/venture arm of Cardinal Health, the third major US pharma distributor. Directly comparable to Cencora Ventures as a healthcare distribution-led CVC, pursuing similar startup investment themes in supply chain and care delivery.
• Oncology Ventures: Specialized early-stage VC focused on oncology. Direct peer given oncology focus and repeated co-investment alongside Cencora Ventures (e.g., both NexCure and RISA Labs rounds), representing a specialized fund that Cencora Ventures partners with on thematic deals.

Broad incumbents

• Johnson & Johnson Innovation: Healthcare CVC arm of J&J, investing across pharma, medtech, and consumer health. A larger, more diversified corporate venture fund pursuing similar healthcare startup opportunities with the strategic backing of a global healthcare giant, comparable to Cencora Ventures' structure.
• Merck Global Health Innovation Fund: CVC of Merck & Co. investing in digital health, therapeutics, and services. Highly comparable as a strategic healthcare corporate venture fund with similar dual-mandate dynamics and pharma-industry parent backing.
• Pfizer Ventures: Corporate venture arm of Pfizer investing in emerging biotech and healthcare technology. A natural peer to Cencora Ventures given comparable healthcare CVC structure, pharma-industry parent, and focus on early-stage opportunities.
• New Enterprise Associates (NEA) Healthcare: Large generalist VC with significant healthcare practice. Broader incumbent peer competing for similar healthcare Series A deals and providing comparison points on healthcare venture returns at scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/CencoraGlobal
• Facebookfacebook.com/Cencora
• LinkedInlinkedin.com/company/cencoraglobal
• Instagraminstagram.com/cencoraglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cencora Ventures